交易 Arrowhead Pharma - ARWR CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | 0.08 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Arrowhead Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 33.57 | 0.10 | 0.30% | 33.47 | 33.75 | 32.95 |
May 25, 2023 | 33.54 | -1.82 | -5.15% | 35.36 | 35.37 | 33.06 |
May 24, 2023 | 35.54 | -0.28 | -0.78% | 35.82 | 35.97 | 35.08 |
May 23, 2023 | 36.23 | -0.25 | -0.69% | 36.48 | 38.51 | 36.23 |
May 22, 2023 | 36.47 | 0.20 | 0.55% | 36.27 | 37.01 | 36.27 |
May 19, 2023 | 36.22 | -0.34 | -0.93% | 36.56 | 37.06 | 36.13 |
May 18, 2023 | 36.23 | -0.58 | -1.58% | 36.81 | 36.81 | 35.43 |
May 17, 2023 | 37.07 | -0.54 | -1.44% | 37.61 | 37.61 | 36.58 |
May 16, 2023 | 37.59 | -1.42 | -3.64% | 39.01 | 39.01 | 37.36 |
May 15, 2023 | 39.83 | 0.75 | 1.92% | 39.08 | 40.83 | 38.86 |
May 12, 2023 | 39.29 | 0.32 | 0.82% | 38.97 | 39.40 | 38.00 |
May 11, 2023 | 40.00 | -0.05 | -0.12% | 40.05 | 40.42 | 39.40 |
May 10, 2023 | 40.44 | -0.68 | -1.65% | 41.12 | 41.12 | 39.29 |
May 9, 2023 | 40.43 | 0.57 | 1.43% | 39.86 | 40.94 | 39.15 |
May 8, 2023 | 40.41 | -0.57 | -1.39% | 40.98 | 41.15 | 39.49 |
May 5, 2023 | 41.30 | 1.21 | 3.02% | 40.09 | 42.42 | 40.09 |
May 4, 2023 | 40.01 | 0.04 | 0.10% | 39.97 | 40.41 | 38.41 |
May 3, 2023 | 40.12 | 3.00 | 8.08% | 37.12 | 40.58 | 36.46 |
May 2, 2023 | 35.28 | -0.14 | -0.40% | 35.42 | 35.89 | 34.54 |
May 1, 2023 | 35.70 | 1.31 | 3.81% | 34.39 | 35.83 | 34.31 |
Arrowhead Pharma Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Thursday, June 1, 2023 | ||
时间(协调世界时) (UTC) 13:00 | 国家/地区 US
| 事件 Arrowhead Pharmaceuticals Inc R&D Day Arrowhead Pharmaceuticals Inc R&D DayForecast -Previous - |
Wednesday, August 2, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 国家/地区 US
| 事件 Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Release Q3 2023 Arrowhead Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 243.231 | 138.287 | 87.9921 | 168.796 | 16.1423 |
收入 | 243.231 | 138.287 | 87.9921 | 168.796 | 16.1423 |
总营业费用 | 421.738 | 287.323 | 181.151 | 107.605 | 72.0786 |
销售/一般/行政费用,总计 | 130.095 | 80.08 | 51.6649 | 26.5563 | 19.1101 |
研究与开发 | 281.222 | 198.977 | 123.543 | 81.0487 | 52.9685 |
Depreciation / Amortization | 10.421 | 8.266 | 5.943 | ||
异常费用(收入) | 0 | ||||
Other Operating Expenses, Total | 0 | ||||
营业收入 | -178.507 | -149.036 | -93.1588 | 61.1906 | -55.9362 |
利息收入(费用),非经营净值 | 5.033 | 6.12 | 9.1905 | 6.95777 | 1.48066 |
Gain (Loss) on Sale of Assets | |||||
其他,净值 | 0.765 | 2.07 | -0.58252 | 0 | 0.00749 |
税前净收入 | -172.709 | -140.846 | -84.5508 | 68.1484 | -54.4481 |
税后净收入 | -176.494 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
少数股东权益 | 0.431 | ||||
未计算非常项目前的净收益 | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
净收入 | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
普通股股东可获收益 (不含非经常性项目) | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
普通股股东可获收益 (含非經常性項目) | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
摊薄净收入 | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
摊薄后加权平均股 | 105.426 | 103.745 | 100.722 | 98.6078 | 83.6385 |
扣除特别项目的每股摊薄盈利 | -1.67001 | -1.35764 | -0.83947 | 0.68935 | -0.65102 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常摊薄盈利 | -1.67001 | -1.35764 | -0.83947 | 0.68935 | -0.65102 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 146.267 | 62.546 | 31.575 | 32.412 | 151.805 |
收入 | 146.267 | 62.546 | 31.575 | 32.412 | 151.805 |
总营业费用 | 98.102 | 104.68 | 115.405 | 105.321 | 110.252 |
销售/一般/行政费用,总计 | 25.159 | 22.651 | 31.624 | 32.738 | 33.863 |
研究与开发 | 70.273 | 79.34 | 81.121 | 69.98 | 73.804 |
Depreciation / Amortization | 2.67 | 2.689 | 2.66 | 2.603 | 2.585 |
营业收入 | 48.165 | -42.134 | -83.83 | -72.909 | 41.553 |
利息收入(费用),非经营净值 | -0.497 | -0.167 | 1.583 | 1.24 | 1.054 |
其他,净值 | 0.008 | 0.507 | 0.09 | -0.377 | 1.759 |
税前净收入 | 47.676 | -41.794 | -82.157 | -72.046 | 44.366 |
税后净收入 | 47.676 | -41.811 | -85.942 | -72.046 | 44.366 |
未计算非常项目前的净收益 | 48.675 | -41.325 | -85.511 | -72.046 | 44.366 |
净收入 | 48.675 | -41.325 | -85.511 | -72.046 | 44.366 |
普通股股东可获收益 (不含非经常性项目) | 48.675 | -41.325 | -85.511 | -72.046 | 44.366 |
普通股股东可获收益 (含非經常性項目) | 48.675 | -41.325 | -85.511 | -72.046 | 44.366 |
摊薄净收入 | 48.675 | -41.325 | -85.511 | -72.046 | 44.366 |
摊薄后加权平均股 | 108.143 | 106.039 | 105.885 | 105.753 | 107.929 |
扣除特别项目的每股摊薄盈利 | 0.4501 | -0.38972 | -0.80758 | -0.68127 | 0.41107 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | 0.4501 | -0.38972 | -0.80758 | -0.68127 | 0.41107 |
少数股东权益 | 0.999 | 0.486 | 0.431 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 405.299 | 384.597 | 322.37 | 265.247 | 78.7686 |
现金和短期投资 | 376.396 | 367.789 | 315.492 | 258.704 | 76.5334 |
现金等价物 | 108.005 | 184.434 | 143.583 | 221.804 | 30.1332 |
短期投资 | 268.391 | 183.355 | 171.909 | 36.8999 | 46.4002 |
应收账款总额,净额 | 1.41 | 10.255 | 0.84567 | 0.66136 | 0.32738 |
Accounts Receivable - Trade, Net | 1.41 | 10.255 | 0.84567 | 0.66136 | 0.32738 |
Prepaid Expenses | 7.289 | 4.362 | 4.2509 | 3.318 | 1.26772 |
Other Current Assets, Total | 20.204 | 2.191 | 1.78169 | 2.56344 | 0.64012 |
Total Assets | 691.939 | 710.148 | 522.504 | 349.845 | 111.61 |
Property/Plant/Equipment, Total - Net | 168.588 | 66.021 | 47.0179 | 23.2149 | 13.9354 |
Property/Plant/Equipment, Total - Gross | 200.142 | 88.885 | 63.3224 | 35.2966 | 23.7408 |
Accumulated Depreciation, Total | -31.554 | -22.864 | -16.3044 | -12.0816 | -9.80536 |
Intangibles, Net | 11.962 | 13.663 | 15.3631 | 17.0636 | 18.764 |
Other Long Term Assets, Total | 0.218 | 0.272 | 0.26536 | 0.14415 | 0.14192 |
Total Current Liabilities | 138.85 | 146.536 | 40.6814 | 97.0707 | 12.365 |
Accounts Payable | 2.868 | 9.457 | 6.82891 | 7.64992 | 2.8061 |
Accrued Expenses | 61.883 | 26.024 | 14.5442 | 11.4606 | 8.98069 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.22382 | |||
Other Current Liabilities, Total | 74.099 | 111.055 | 19.3083 | 77.9601 | 0.35434 |
Total Liabilities | 293.419 | 301.326 | 60.7246 | 105.254 | 15.8138 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 2.1012 |
Long Term Debt | 0 | 2.1012 | |||
Capital Lease Obligations | |||||
Minority Interest | 19.819 | 0 | -0.55519 | -0.55519 | |
Other Liabilities, Total | 134.75 | 154.79 | 20.0432 | 8.73851 | 1.9028 |
Total Equity | 398.52 | 408.822 | 461.779 | 244.591 | 95.7962 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.198 | 0.197 | 0.19475 | 0.18788 | 0.18088 |
Additional Paid-In Capital | 1219.21 | 1053.39 | 965.41 | 664.086 | 582.903 |
Retained Earnings (Accumulated Deficit) | -820.755 | -644.692 | -503.844 | -419.291 | -487.266 |
Other Equity, Total | -0.136 | -0.069 | 0.01843 | -0.39162 | -0.02156 |
Total Liabilities & Shareholders’ Equity | 691.939 | 710.148 | 522.504 | 349.845 | 111.61 |
Total Common Shares Outstanding | 105.96 | 104.327 | 102.376 | 95.5063 | 88.5053 |
Total Preferred Shares Outstanding | |||||
Long Term Investments | 105.872 | 245.595 | 137.487 | 44.176 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 574.81 | 574.999 | 405.299 | 432.388 | 417.63 |
现金和短期投资 | 481.005 | 501.831 | 376.396 | 416.496 | 401.895 |
现金等价物 | 134.959 | 202.249 | 108.005 | 139.439 | 86.408 |
短期投资 | 346.046 | 299.582 | 268.391 | 277.057 | 315.487 |
应收账款总额,净额 | 69.434 | 39.568 | 1.41 | 0.239 | 1.317 |
Accounts Receivable - Trade, Net | 69.434 | 39.568 | 1.41 | 0.239 | 1.317 |
Prepaid Expenses | 9.935 | 8.412 | 7.289 | 6.761 | 6.622 |
Other Current Assets, Total | 14.436 | 25.188 | 20.204 | 8.892 | 7.796 |
Total Assets | 891.308 | 891.489 | 691.939 | 751.782 | 703.575 |
Property/Plant/Equipment, Total - Net | 226.342 | 188.969 | 168.588 | 140.812 | 71.267 |
Property/Plant/Equipment, Total - Gross | 262.414 | 222.804 | 200.142 | 170.147 | 98.448 |
Accumulated Depreciation, Total | -36.072 | -33.835 | -31.554 | -29.335 | -27.181 |
Intangibles, Net | 11.112 | 11.537 | 11.962 | 12.387 | 12.813 |
Long Term Investments | 78.834 | 115.774 | 105.872 | 165.92 | 201.59 |
Other Long Term Assets, Total | 0.21 | 0.21 | 0.218 | 0.275 | 0.275 |
Total Current Liabilities | 87.151 | 122.009 | 138.85 | 128.212 | 138.857 |
Accounts Payable | 9.556 | 0.796 | 2.868 | 5.894 | 10.603 |
Accrued Expenses | 47.756 | 54.932 | 61.883 | 38.03 | 30.385 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 29.839 | 66.281 | 74.099 | 84.288 | 97.869 |
Total Liabilities | 444.536 | 514.45 | 293.419 | 297.855 | 251.309 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 339.051 | 373.108 | 134.75 | 149.393 | 112.452 |
Total Equity | 446.772 | 377.039 | 398.52 | 453.927 | 452.266 |
Common Stock | 0.199 | 0.199 | 0.198 | 0.198 | 0.198 |
Additional Paid-In Capital | 1260.31 | 1239.18 | 1219.21 | 1189.11 | 1115.37 |
Retained Earnings (Accumulated Deficit) | -813.405 | -862.08 | -820.755 | -735.244 | -663.198 |
Other Equity, Total | -0.332 | -0.258 | -0.136 | -0.14 | -0.107 |
Total Liabilities & Shareholders’ Equity | 891.308 | 891.489 | 691.939 | 751.782 | 703.575 |
Total Common Shares Outstanding | 106.869 | 106.14 | 105.96 | 105.795 | 105.702 |
Minority Interest | 18.334 | 19.333 | 19.819 | 20.25 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -176.494 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
经营活动产生的现金 | -136.131 | 171.224 | -95.3916 | 173.035 | -47.2234 |
经营活动产生的现金 | 10.421 | 8.267 | 5.94226 | 4.43914 | 4.69928 |
非现金物品 | 128.235 | 76.939 | 43.9083 | 13.4624 | 8.40554 |
Cash Taxes Paid | 0.002 | 0.002 | -0.10344 | 0.3024 | 0.0024 |
已付现金利息 | 0 | 0 | 0 | 0.02744 | 0.17338 |
营运资金的变化 | -98.293 | 226.866 | -60.6889 | 87.1585 | -5.87776 |
投资活动产生的现金 | -5.417 | -141.678 | -240.778 | -47.746 | -7.43496 |
资本支出 | -52.777 | -23.567 | -11.9517 | -12.0012 | -1.42125 |
其他投资现金流量项目,总计 | 47.36 | -118.111 | -228.826 | -35.7448 | -6.01371 |
融资活动产生的现金 | 65.186 | 11.305 | 257.948 | 66.382 | 59.953 |
融资现金流项目 | 60 | 0 | 0 | -0.05467 | |
股票的发行(报废),净额 | 5.186 | 11.305 | 257.948 | 68.7971 | 60.2162 |
债务的发行(退还),净额 | 0 | -2.41515 | -0.20851 | ||
现金净变化 | -76.429 | 40.851 | -78.2215 | 191.671 | 5.29465 |
外汇效应 | -0.067 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 5.865 | -41.811 | -176.494 | -90.552 | -18.506 |
Cash From Operating Activities | -107.187 | -75.516 | -136.131 | -67.464 | 1.383 |
Cash From Operating Activities | 5.358 | 2.689 | 10.421 | 7.761 | 5.167 |
Non-Cash Items | 47.826 | 22.929 | 128.235 | 99.465 | 62.789 |
Changes in Working Capital | -166.236 | -59.323 | -98.293 | -84.138 | -48.067 |
Cash From Investing Activities | -116.759 | -80.694 | -5.417 | -41.862 | -103.14 |
Capital Expenditures | -66.225 | -38.911 | -52.777 | -20.066 | -10.53 |
Other Investing Cash Flow Items, Total | -50.534 | -41.783 | 47.36 | -21.796 | -92.61 |
Cash From Financing Activities | 251.096 | 250.576 | 65.186 | 64.331 | 3.731 |
Issuance (Retirement) of Stock, Net | 1.096 | 0.576 | 5.186 | 4.331 | 3.731 |
Net Change in Cash | 26.954 | 94.244 | -76.429 | -44.995 | -98.026 |
Cash Taxes Paid | 0 | 0 | |||
Cash Interest Paid | 0 | 0 | |||
Financing Cash Flow Items | 250 | 250 | 60 | 60 | |
Foreign Exchange Effects | -0.196 | -0.122 | -0.067 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 10.8288 | 11575992 | 32030 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.9771 | 10665598 | 401699 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.5217 | 5902768 | -67576 | 2023-03-31 | LOW |
Anzalone (Christopher Richard) | Individual Investor | 3.4805 | 3720714 | 0 | 2023-05-04 | MED |
Invesco Advisers, Inc. | Investment Advisor | 1.9738 | 2109950 | 4029 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9444 | 2078527 | 104976 | 2023-03-31 | LOW |
JP Morgan Asset Management | Investment Advisor | 1.7531 | 1874095 | 281642 | 2023-03-31 | LOW |
Avidity Partners Management LP | Hedge Fund | 1.6289 | 1741300 | 366300 | 2023-03-31 | HIGH |
Rokos Capital Management LLP | Hedge Fund | 1.5677 | 1675921 | 1274999 | 2023-03-31 | HIGH |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.3892 | 1485073 | 544004 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.2846 | 1373247 | -616286 | 2023-03-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 1.153 | 1232545 | 8305 | 2023-03-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 1.092 | 1167363 | 22669 | 2023-03-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 1.0829 | 1157575 | 19132 | 2023-03-31 | LOW |
First Manhattan Co. LLC | Investment Advisor | 0.9594 | 1025654 | 0 | 2023-03-31 | LOW |
Aquilo Capital Management, LLC | Investment Advisor/Hedge Fund | 0.9527 | 1018474 | -85041 | 2023-03-31 | |
Millennium Management LLC | Hedge Fund | 0.9068 | 969394 | 393770 | 2023-03-31 | HIGH |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.878 | 938585 | 1607 | 2023-03-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.7935 | 848305 | 204332 | 2023-03-31 | HIGH |
Western Financial Corporation | Investment Advisor | 0.7674 | 820320 | 0 | 2023-03-31 | LOW |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Arrowhead Pharma Company profile
关于 Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc.开发的药物通过抑制导致疾病的基因来治疗难治性疾病。 公司使用核糖核酸(RNA)化学组合和给药方式,公司的疗法触发了RNA干扰机制,以诱导快速、深入和持久地击倒目标基因。 公司专注于开发具有遗传基础的疾病的药物,其特点是一种或多种蛋白质的过度生产。 公司的产品线包括治疗高甘油三酯血症的ARO-APOC3,治疗血脂异常的ARO-ANG3,治疗肝病的ARO-HSD,治疗囊性纤维化的ARO-ENaC,治疗肾细胞癌的ARO-HIF2。 ARO-DUX4用于面肌萎缩症,ARO-LUNG2用于慢性阻塞性肺病,ARO-COV用于引起COVID-19的冠状病毒和其他未来可能的肺部传播病原体。
Industry: | Bio Therapeutic Drugs |
177 E Colorado Blvd
Suite 700
PASADENA
CALIFORNIA 91105
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球530,000万多名交易者的一份子,选择利用Capital.com进行交易吧。